Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Metastasis Inhibition and Immunotherapy Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for Moesin (MSN) drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | Recombinant Moesin (MSN) Protein / FERM Domain High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Suitable for binding assays and structural analysis. |
View MSN Products |
| Gene Delivery | Moesin (MSN) Promise-ORF / Lentivirus Full-length ORF for stable cell line generation. Crucial for functional cell migration and invasion assays. |
View MSN Products |
| Benchmark Ab | Anti-Moesin (MSN) Recombinant Antibody Recombinant positive control for flow cytometry, IHC, and functional blocking validation. |
View MSN Products |
| Validator | Moesin (MSN) siRNA Set Target-specific knockdown verification to confirm phenotype specificity in vitro. |
View MSN Products |
| Related Target A | Ezrin (EZR) High homology ERM family member. Critical for off-target counter-screening and selectivity profiling. |
View EZR Products |
| Related Target B | Radixin (RDX) ERM family member sharing structural conservation. Essential for evaluating pan-ERM vs. selective MSN inhibitors. |
View RDX Products |
| Related Target C | CD44 Key cell-surface adhesion receptor that interacts directly with the FERM domain of Moesin to drive EMT. |
View CD44 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| ERM Family Off-Target Cross-Reactivity | Highly purified recombinant MSN, EZR, and RDX proteins available (>95% purity by SDS-PAGE) for precise selectivity panels. |
| Conformation-Dependent Binding Evaluation | HEK293 expressed proteins preserving native post-translational modifications and folded domains (FERM vs. C-terminal). |
| Lack of Controls | Sequence-verified clinical-grade benchmark recombinant antibodies included in our catalog. |
| False Positives | Validated siRNA sets included to confirm that migration inhibition is directly linked to MSN knockdown. |
Live Moesin (MSN) R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for Moesin (MSN) therapeutics is intensifying, with major players shifting focus from traditional intracellular scaffolding roles to targeting extracellularly translocated Moesin (eMSN) in oncology and inflammatory diseases. As first-generation therapies reach the clinic, the next wave of R&D is targeting the specific disruption of the Moesin-CD44 interaction to halt the Epithelial-Mesenchymal Transition (EMT) and overcome chemotherapy resistance.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibodies (anti-eMSN) | Biotech Innovators, Academic Medical Centers | Triple-Negative Breast Cancer (TNBC), Glioblastoma, Pancreatic Cancer | Cell surface binding assays (Need MSN Lentivirus for stable cell line construction) |
| Small Molecule Inhibitors (FERM domain) | Preclinical Oncology Startups | Metastatic Melanoma, Advanced Solid Tumors | High-throughput screening & SPR (Need high-purity recombinant MSN FERM domain protein) |
| RNA Therapeutics (siRNA/ASO) | RNAi Therapeutics Developers | Inflammatory Diseases, Fibrosis | In vitro knockdown validation (Need sequence-verified MSN siRNA sets) |